Evotec and Janssen team up to develop immune-based therapies
Evotec has entered into a strategic collaboration and licence agreement with Janssen Biotech: with the partnership focusing on developing targeted immune-based therapies for oncology.
Archives for January 30, 2023
Sandoz bags positive EU opinion for higher strength adalimumab biosimilar
Novartis subsidiary, Sandoz, has secured a postive option from an EMA commitee in relation to its high concentration and citrate-free adalimumab biosimilar
Dupixent approved in EU as first and only targeted medicine for eosinophilic esophagitis
The European Commission (EC) has expanded the marketing authorization for Regeneron and Sanofi’s Dupixent (dupilumab) in the European Union (EU) to treat eosinophilic esophagitis (EoE).
US senators raise concerns over Moderna’s planned COVID-19 vaccine price hike
US senators, Elizabeth Warren and Peter Welch, are urging Moderna to reconsider the proposed price increases for its COVID-19 vaccines.
Once-weekly efanesoctocog alfa data shows ‘potential to transform the treatment landscape for hemophilia A’, says Sanofi
Phase 3 data for efanesoctocog alfa has been published in the New England Journal of Medicine (NEJM): ahead of a decision on the therapy by the US Food and Drug Administration (FDA) at the end of next month.